SOPHiA GENETICS SA (NASDAQ:SOPH) Receives $10.00 Consensus PT from Brokerages

SOPHiA GENETICS SA (NASDAQ:SOPH) has been given an average recommendation of “Hold” by the five research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $10.00.

Several equities research analysts recently weighed in on the stock. HC Wainwright increased their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. BTIG Research lifted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st.

SOPHiA GENETICS Price Performance

SOPH stock opened at $8.65 on Monday. The firm has a market cap of $725.65 million, a price-to-earnings ratio of -7.52 and a beta of 0.96. SOPHiA GENETICS has a 1-year low of $3.10 and a 1-year high of $8.68. The firm has a fifty day moving average price of $6.18 and a two-hundred day moving average price of $5.32. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. Research analysts predict that SOPHiA GENETICS will post -0.77 EPS for the current year.

Insider Activity at SOPHiA GENETICS

In related news, CEO Jurgi Camblong sold 50,069 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20. Following the completion of the transaction, the chief executive officer directly owned 3,601,493 shares in the company, valued at $20,888,659.40. This represents a 1.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 17,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $7.29, for a total value of $123,930.00. Following the completion of the sale, the insider directly owned 590,887 shares in the company, valued at $4,307,566.23. This represents a 2.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 318,592 shares of company stock worth $1,952,315 in the last 90 days. 4.88% of the stock is currently owned by company insiders.

Institutional Trading of SOPHiA GENETICS

A number of large investors have recently modified their holdings of the company. AXQ Capital LP bought a new stake in SOPHiA GENETICS in the 2nd quarter valued at about $119,000. AWM Investment Company Inc. acquired a new position in SOPHiA GENETICS during the 2nd quarter valued at about $9,809,000. Hennion & Walsh Asset Management Inc. bought a new position in SOPHiA GENETICS in the 2nd quarter worth about $567,000. Royal Bank of Canada grew its position in SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at approximately $1,772,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.